This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“Cholesterol does not cause heart disease.“ “ “Statins do not prevent heartattacks.” In the middle of this hurricane of noise are people who just want to know what to do so they don’t have a heartattack at a young age. “Statins do not prevent heartattacks.”
For every 20mmHg increase in systolic (Top Number) blood pressure, the risk of dying from a heartattack or stroke doubles 3. In general, the more plaque you have, the higher your risk of a heartattack over the next 10 years. 6, 2017 7 JACC: Cardiovascular Imaging May 2015, 8 (5) 579-596; J Am Coll Cardiol.
This refers to all the steps necessary to reduce the odds of a subsequent event, such as a second heartattack or stroke. So, let’s cover seven things that reduce the risk of a subsequent heartattack. This is a program that starts the day of your heartattack. Cardiac Rehabilitation.
Cardiovascular disease is the most common cause of death and disability globally, largely driven by myocardial infarction and ischemic stroke caused by atherosclerosis (plaque build-up in the arteries). 2017 23, April 2020; Available from: [link]. Hafiane, Vulnerable plaque, characteristics, detection, and potential therapies , J.
3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heartattack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 milligrams per liter (mg/L) are linked to increased risk of heartattacks or risk of a repeat heartattack.23
Over time, hypertension weakens the heart, blood vessels and kidneys, paving the way for potential stroke or heartattack. Often referred to as the “silent killer,” high blood pressure is a leading risk factor for heart disease and early death.
This leaves a gap in the care of these patients and increases their risk for heartattack, stroke and heart failure progression. HTN accelerates the progression of atherosclerosis and leads to increased risk of major cardiac events like heartattack, heart failure, kidney disease and other end organ damage.
Reducing Hospitalizations by Detecting Early Warning Signs One of the biggest cost drivers in cardiovascular care is unplanned hospitalizations due to acute cardiac events like heartattacks and strokes. since March 2017.He Stuart LongStuart Long has been the CEO of infobionic.ai
Since 2017, a plethora of AI-based algorithms for interpreting ECGs have been approved by the FDA in the US, ranging from the detection and diagnosis of arrythmias, to more recent advances in the diagnoses of structural and ischemic diseases.
The aim is to reduce death and damage from nasty things such as heartattacks and strokes. With diabetes, the aim is also to reduce heartattacks and strokes… additionally kidney failure, and amputations, and blindness. It makes up a significant portion of their income. The aim of all this?
Discovering discrepancies in a major published trial from the pharma-academic complex would be a boost to those seeking to force trial data to be public, and that is exactly what a group of investigators attempted to do with a major cholesterol lowering trial published in 2017. But first, some background. Cholesterol lowering is big business.
But remember, heart disease or atherosclerosis does not kill people. Heartattacks kill people. A heartattack occurs when plaque in your coronary artery ruptures and causes a clot to form, which stops blood flow to the heart muscle, causing it to die. 2017 Apr;91:1-9. Vascul Pharmacol.
This misinformation would have resulted in many thousands of people giving up their medication and suffering heartattacks and strokes as a result. Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M With thousands dying. I make no claim to be Nostradamus 2.0.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content